PMID- 25426071
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20141126
LR  - 20200930
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 5
DP  - 2014
TI  - Inside epoxyeicosatrienoic acids and cardiovascular disease.
PG  - 239
LID - 10.3389/fphar.2014.00239 [doi]
LID - 239
AB  - Epoxyeicosatrienoic acids (EETs) generated from arachidonic acid through 
      cytochrome P450 (CYP) epoxygenases have many biological functions. Importantly, 
      CYP epoxygenase-derived EETs are involved in the maintenance of cardiovascular 
      homeostasis. In fact, in addition to their potent vasodilating effect, EETs have 
      potent anti-inflammatory properties, inhibit platelet aggregation, promote 
      fibrinolysis, and reduce vascular smooth muscle cell proliferation. All EETs are 
      metabolized to the less active dihydroxyeicosatrienoic acids by soluble epoxide 
      hydrolase (sEH). Numerous evidences support the role of altered EET biosynthesis 
      in the pathophysiology of hypertension and suggest the utility of 
      antihypertensive strategies that increase CYP-derived EET or EET analogs. Indeed, 
      a number of studies have demonstrated that EET analogs and sEH inhibitors induce 
      vasodilation, lower blood pressure and decrease inflammation. Some of these 
      agents are currently under evaluation in clinical trials for treatment of 
      hypertension and diabetes. However, the role of CYP epoxygenases and of the 
      metabolites generated in cancer progression may limit the use of these drugs in 
      humans.
FAU - Tacconelli, Stefania
AU  - Tacconelli S
AD  - Department of Neuroscience, Imaging and Clinical Science, Center of Excellence on 
      Aging (CeSI), "Gabriele d'Annunzio" University Chieti, Italy.
FAU - Patrignani, Paola
AU  - Patrignani P
AD  - Department of Neuroscience, Imaging and Clinical Science, Center of Excellence on 
      Aging (CeSI), "Gabriele d'Annunzio" University Chieti, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20141110
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC4226225
OTO - NOTNLM
OT  - cytochrome P450
OT  - epoxyeicosatrienoic acids
OT  - epoxygenases
OT  - hypertension
OT  - soluble epoxide hydrolase
EDAT- 2014/11/27 06:00
MHDA- 2014/11/27 06:01
PMCR- 2014/11/10
CRDT- 2014/11/27 06:00
PHST- 2014/08/01 00:00 [received]
PHST- 2014/10/22 00:00 [accepted]
PHST- 2014/11/27 06:00 [entrez]
PHST- 2014/11/27 06:00 [pubmed]
PHST- 2014/11/27 06:01 [medline]
PHST- 2014/11/10 00:00 [pmc-release]
AID - 10.3389/fphar.2014.00239 [doi]
PST - epublish
SO  - Front Pharmacol. 2014 Nov 10;5:239. doi: 10.3389/fphar.2014.00239. eCollection 
      2014.